Replies to post #64482 on NorthWest Biotherapeutics Inc (NWBO)

[Finding the Truth]

Great Question! Can a trial finish if it hasn't even fully enrolled?

I love the question you brought up because this is a huge reason why I invested in NWBO recently after being gone for so long. Although I am a young investor to my understanding of this trial that it will end at 248 events no matter what and having complete enrollment is not as important. We know that there are over 300 patients enrolled. We know before the trial resized that it use be 312 patients to complete enrollment. It is very possible that NWBO has about 312 or more patients currently enrolled. If NWBO reached 248 events some time this year. Wouldn't NWBO just need the PFS and OS to be greater than the amount given before the resize in trial happened?

[beartrap12]

ARGS has 100 employees? So let's assume the average yearly salary is $50,000 or more. That's $5million per year going toward salaries. Then you have to add in the cost of the clean rooms they need to rent or own and the cost of the equipment they probably bought and must maintain. Maybe another $5 million a year.
Perhaps somebody on the board has a grasp of those costs.
So we're already at $10 million a year that ARGS has spent internally, but which NWBO contracts out to Cognate. On top of that Cognate has employees who worked with Dr. Bosch developing the almost completely automated system that NWBO has patents and which will make their treatment more cost effective. We know Dr. Bosch uses Cognate employees to Devon new patents processes because he names them and thanks them in his slide presentations. Besides making vaccines, Cognate also trains employees at every one of the 80 plus sites that have been set up in the trial.
So are we really spending more using Cognate than ARGS and other small bios using. Internal people?